Literature Scan

Literature Scan

New and noteworthy research from the medial literature landscape

New Research Identifies W491 as a Potential Therapeutic Target in Essential Thrombocythemia

In patients with familial essential thrombocythemia (ET) negative for JAK2, CALR, or MPL W515 mutation (triple-negative), newly identified MPL mutations elucidate a broad mechanism...

Ropeginterferon Alfa-2b Leads to More Durable Responses Than Hydroxyurea in PV

Patients with polycythemia vera were more likely to achieve durable long-term hematologic response with ropeginterferon alfa-2b than the standard cytoreductive therapy hydroxyurea, according to...

Venetoclax Plus High-Dose Cytarabine With or Without Idarubicin Well Tolerated in Pediatric AML

In a small study of children and young adults with relapsed or refractory acute myeloid leukemia (AML), venetoclax plus cytarabine chemotherapy, with or without...

Comparing Risks of Hypophosphatemia With Intravenous Formulations in Iron-Deficiency Anemia

For patients with iron-deficiency anemia who are intolerant of or unresponsive to oral iron, intravenous formulations can rapidly correct iron deficiency, but certain formulations...

Venetoclax Plus Low-Dose Cytarabine Improves Survival and Remission in Patients With Chemotherapy-Ineligible AML

Treatment with venetoclax plus low-dose cytarabine (LDAC) led to greater improvements in remission and overall survival (OS), compared with LDAC alone, in patients with...

Clonal Hematopoiesis, Aberrant CD7 Expression Linked to Post-AHCT Therapy-Related Myeloid Neoplasms

Low variant allele frequency (VAF) clonal hematopoiesis, aberrant CD7 expression on hematopoietic stem cells, and specific gene mutations at the time of autologous hematopoietic...

Chk1 Inhibition Shows Efficacy for Splicing Factor Mutant MDS and Leukemia

A new study found Chk1 inhibition with or without splicing modulators may be an effective targeted treatment approach for splicing factor mutant myelodysplastic syndromes...

2017 European LeukemiaNet Risk Groups Predict Prognosis in FLT3-ITD AML

Genetic risk groups defined by the 2017 European LeukemiaNet (ELN) recommendations may reliably predict prognosis in patients with acute myeloid leukemia (AML) and internal...

Luspatercept Reduces Anemia Severity, Improves Rate of Transfusion Independence in MDS

Compared with placebo, treatment with luspatercept improved the 12- to 16-week rate of red blood cell (RBC) transfusion independence in patients with lower-risk myelodysplastic...

Hemophilia A Gene Therapy Offers Sustained Clinical Benefit

In men with severe hemophilia A, treatment with an adeno-associated virus serotype 5 (AAV5) vector containing a B-domain-deleted factor VIII (FVIII) gene, known as...
Advertisement

Current Issue

August 2020 Volume 6, Issue 10

This issue looks at the rapid expansion of telemedicine, explores access to leukemia treatment in Brazil, and more.

Block title